Skip to main content
TipRanks
Go Ultimate75% OFF

Accendra Health (ACCH) AI Stock Analysis

570 Followers
ACCH

Accendra Health

(Other OTC:ACCH)

Select Model
Rating:41Neutral
Price Target:$0.08â–²(326.32% Upside)
Action:upgraded
Date:11/17/26

ACH scores low primarily due to high fundamental risk (negative equity, revenue decline, and continued losses) and a sharply bearish technical setup (price far below moving averages with negative MACD). Offsetting factors are limited to improved recent cash generation and liquidity/turnaround initiatives discussed on the earnings call, but these are tempered by reduced EBITDA guidance and ongoing operational underperformance.

Positive Factors
Improved cash generationThe return to positive operating and free cash flow improves internal funding capacity and provides evidence that stabilization efforts are beginning to convert into cash. However, sustaining this improvement remains important because prior cash generation was volatile and recent operating cash flow is modest relative to business scale.
Negative Factors
Negative stockholders’ equityNegative equity indicates a materially weakened capital structure and reduces financial flexibility even though total debt has declined. It can complicate refinancing and credit access, making execution more dependent on reliable cash generation and successful improvement in operating performance.

Accendra Health (ACCH) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%ACCH-99.29%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.49M
Dividend Yield
―
Average Volume (3M)
2.96M
Price to Earnings (P/E)
-0.0
Beta (1Y)
1.36
Revenue Growth
-61.96%
EPS Growth
87.15%
Country
US
Employees
6,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Accendra Health Business Overview & Revenue Model

Company Description

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, includi...

Accendra Health Financial Statement Overview

Summary

Operations show stabilization (losses narrowed vs. 2024–2025) and TTM free cash flow is positive (~$121M), but overall fundamentals remain weak: TTM revenue declined (-3.6%), net margin is still negative (~-6.7%), and the balance sheet is high risk with negative stockholders’ equity (reduced financial flexibility despite lower total debt).

Income Statement

34Negative

Balance Sheet

18Very Negative

Cash Flow

52Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.55B2.76B10.70B10.33B9.96B9.79B
Gross Profit1.13B1.29B2.22B2.13B1.83B1.51B
EBITDA141.09M219.75M51.22M390.57M368.45M415.46M
Net Income-171.56M-1.10B-362.69M-41.30M22.39M221.59M
Balance Sheet
Total Assets2.08B2.45B4.66B5.09B5.39B3.54B
Cash, Cash Equivalents and Short-Term Investments26.61M281.99M49.38M243.04M69.47M55.71M
Total Debt1.85B2.23B2.14B2.41B2.79B1.15B
Total Liabilities2.65B2.91B4.09B4.17B4.44B2.60B
Stockholders Equity-568.23M-460.98M565.23M924.17M945.60M938.50M
Cash Flow
Free Cash Flow-163.83M-303.12M-66.67M532.82M158.42M74.49M
Operating Cash Flow-25.31M-101.79M161.50M740.71M325.01M124.18M
Investing Cash Flow313.45M144.42M-116.53M-137.25M-1.80B-53.63M
Financing Cash Flow-307.79M188.08M-267.60M-417.33M1.50B-129.48M

Accendra Health Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.45Negative
100DMA1.41Negative
200DMA2.11Negative

Market Momentum

MACD-0.11Negative
RSI18.07Positive
STOCH1.14Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACCH, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.45, and below the 200-day MA of 2.11, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 18.07 is Positive, neither overbought nor oversold. The STOCH value of 1.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACCH.

Accendra Health Risk Analysis

Accendra Health disclosed 39 risk factors in its most recent earnings report. Accendra Health reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The market price for our common stock does not meet the New York Stock Exchange (NYSE) continued listing requirements and our efforts to cure the noncompliance may be unsuccessful.Q3, 2026
2.Changes in our management team resulting from the hiring or departure of executives and key employees from time to time could disrupt our business.Q3, 2026
3.We have sold our P&HS business, and there may be negative impacts on our financial condition, results of operations, cash flows, capital resources and liquidity.Q4, 2025

Accendra Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ACCH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MEDSMEDS43Neutral$4.23M-0.04356.14%―-77.47%62.15%
ACCHACCH41Neutral$1.49M-0.0433.56%―-61.96%87.15%
YIYI40Underperform$24.50M-1.5623.64%―-23.90%-45.45%
RDGTRDGT33Underperform$3.74M-0.00-3.54%―10.16%98.05%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%ACCHRDGTAHGYIHKPDMEDSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ACCH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ACCHAccendra Health Inc0.02-2.58-99.27%
RDGTRidgetech, Inc.1.03-624.47-99.84%
AHGAkso Health Group Sponsored ADR1.36-0.18-11.82%
YI111, Inc.2.79-0.90-24.44%
HKPDHong Kong Pharma Digital Technology Holdings Ltd.1.33-19.07-93.48%
MEDSDatameds Ai, Inc.0.74-23.69-96.97%

Accendra Health Corporate Events

Business Operations and StrategyFinancial Disclosures

Accendra Health Reports Weak Third-Quarter Financial Results

Negative
Nov 5, 2026

On November 5, 2026, Accendra Health reported third-quarter results for continuing operations for the period ended September 30. Net revenue fell to $601.8 million from $697.3 million a year earlier, while the GAAP loss widened to $18.0 million from...

Executive/Board Changes

Accendra Health Executive Transitions to Strategic Advisor Role

Neutral
Nov 3, 2026

On October 29, 2026, Perry A. Bernocchi, the company’s executive vice president and chief operating officer, entered into a transition agreement concerning his move from executive officer duties to Strategic Advisor to the Chief Executive Officer. Th...

Business Operations and StrategyPrivate Placements and Financing

Accendra Health Extends $150 Million Receivables Program to 2029

Positive
Nov 2, 2026

On October 29, 2026, Accendra Funding LLC and Byram Healthcare Centers, wholly owned subsidiaries of Accendra Health, amended the company’s receivables purchase agreement. The amendment extended the $150 million receivables sale program’s scheduled t...

Delistings and Listing ChangesRegulatory Filings and Compliance

Accendra Health Outlines Plan to Regain NYSE Compliance

Negative
Oct 30, 2026

On October 27, 2026, Accendra Health received notice from the New York Stock Exchange that it was no longer in compliance with listing standards requiring both an average market capitalization and stockholders’ equity of at least $50 million over a 3...

Delistings and Listing ChangesShareholder MeetingsStock Split

Accendra Health Addresses NYSE Listing Price Deficiency

Negative
Oct 9, 2026

On October 6, 2026, Accendra Health received notice from the New York Stock Exchange that its common stock no longer met the exchange’s continued listing standard requiring an average closing price of at least $1 over a consecutive 30‑day trading per...

Business Operations and StrategyExecutive/Board Changes

Accendra Health appoints new CEO and commercial chief

Positive
Sep 17, 2026

On September 17, 2026, Accendra Health named board member Kenneth Gardner-Smith as its next President and Chief Executive Officer, with his transition into the role expected early in the fourth quarter of 2026. He will succeed long-serving CEO Edward...

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A Transactions

Accendra Health Halts Equity Program, Highlights Liquidity Strength

Positive
Aug 17, 2026

On August 17, 2026, Accendra Health announced it will not proceed with a planned at-the-market equity issuance program that was intended to modestly reduce debt, saying the decision, driven by market conditions, will not affect its results or guidanc...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026